Merck-Schering Merger Requires Divestiture of Phase II Antiemetic Due To Emend's Strength
FTC says Schering must divest its NK-1 receptor antagonist relapitant. Merck must also sell its interest in a $2.6 billion animal health joint venture.
FTC says Schering must divest its NK-1 receptor antagonist relapitant. Merck must also sell its interest in a $2.6 billion animal health joint venture.